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Abstract: Amphotericin B (AmpB), one of the most commonly used agents in the treatment of
severe fungal infections and life-threatening parasitic diseases such as visceral Leishmaniasis, has a
negligible oral bioavailability, primarily due to a low solubility and permeability. To develop an
oral formulation, medium chain triglycerides and nonionic surfactants in a self-nano-emulsifying
drug delivery system (SNEDDS) containing AmpB were combined with room temperature ionic
liquids (RTILs) of imidazolium. The presence of ionic liquids significantly enhanced the solubility of
AmpB, exhibited a low toxicity and increased the transport of AmpB across Caco-2 cell monolayers.
The combination of RTILs with a lipid formulation might be a promising strategy to improve the oral
bioavailability of AmpB.
Keywords: self-emulsifying drug delivery systems; amphotericin B; room temperature ionic liquids;
Caco-2 cells; cytotoxicity
1. Introduction
Lipid-based formulations are emerging as an interesting formulation strategy for providing
bioavailability-enhancing mechanisms for poorly water-soluble drugs belonging to Biopharmaceutics
Classification System (BCS) Class II or IV [1,2]. The oral delivery of these drugs is affected by
their low bioavailability and lack of dose solubility [3]. Another important factor that also affects
the oral bioavailability of BCS IV drugs is poor intestinal permeability [3]. Hence, to enhance
their solubility, lipid-based formulations have been successfully used as oral delivery systems [4].
Self-nano-emulsifying drug delivery systems (SNEDDS) are one of the most special and interesting
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lipid-based formulations [4] and are considered as a promising approach for improving the rate and
extent of absorption of BCS II or IV drugs [5,6]. SNEDDS are defined as isotropic mixtures of oils,
surfactants and co-solvents that have a unique ability of forming a fine oil in water nanoemulsions upon
gentle agitation by dilution in an aqueous environment [7–9]. The droplet sizes of these nanoemulsions
are between 20 and 200 nm [8,10]. SNEDDS induce the formation of oil droplets, which in turn may
facilitate the transport of the active across the intestinal membrane [11].
AmpB is a polyene antifungal antibiotic and belongs to BCS Class IV, which is characterized
by a low permeability and low solubility [12]. This drug remains the most effective antifungal
medication for severe fungal infections and visceral Leishmaniasis [13]. Worldwide, 12–15 million
people are infected with visceral Leishmaniasis, and it is estimated that 70,000 deaths are caused every
year [14]. AmpB, when administered orally, shows a poor gastrointestinal absorption and negligible
bioavailability due to the hydrophobicity of its polyene structure (Figure 1a) [15]. However, it should
remain solubilized in the gastrointestinal tract (GIT) to facilitate its absorption across the intestinal
wall. In this context, an attempt was made to incorporate room temperature ionic liquids (RTILs),
which are liquids at ambient temperature, into SNEDDS, as a means of increasing the solubility,
which in turn might increase the absorption of the Active Pharmaceutical Ingredient (API) in the
gastrointestinal tract [16–19]. RTILs are organic salts, and they are often called “designer solvents”
since their physicochemical properties depend on cations and anions which can be varied. Furthermore,
imidazolium or pyridinium ions can be used as organic cations of RTILs, combined with a variety of
anions such as hexafluorophosphate or tetrafluoroborate (Figure 1) [18]. In addition, RTILs appear as
promising candidates for enhancing the aqueous solubility of hydrophobic drugs via the selection of
the adequate cation/anion combinations [20]. RTILs are hydrotropic compounds, which are capable
of substantially increasing the solubility of hydrophobic substances in water. There are three main
hypotheses that have been proposed in order to explain the hydrotropic solubilization. According to the
first approach, a formation of a complex between the solute and the hydrotrope may occur. Furthermore,
the hydrotropes may change the solvent structure around the solute and can be therefore considered
as structure makers or breakers. Finally, the co-aggregation of the solute with the hydrotropes above a
minimum hydrotrope concentration has been proposed as the most likely mechanism [21,22]. On the
other hand, RTILs have generated considerable interest in fields as broad as catalysis, extraction, energy
storage and CO2 capture, but also in skin delivery as permeation enhancers [23,24].Pharmaceutics 2020, 12, x 3 of 15 
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Owing to their properties in the current study, three different types of RTILs of imidazolium, namely
1-Butyl-3-methylimidazolium hexafluorophosphate (BMIMPF6) (Figure 1b), 1-Butyl-3-methylimidazolium
tetrafluoroborate (BMIMBF4) (Figure 1c) and 1-Hexyl-3-methylimidazolium chloride (HMIMCl) (Figure 1d),
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were combined with a SNEDDS preconcentrate (SNEDDS:RTILs) containing AmpB and were further
evaluated in vitro. The RTILs varied in alkyl moieties [bmim, butyl-] and [hmim, hexyl-], and in the type of
anions PF6−, BF4− and Cl−. Previous studies have shown that the type of ion and the length of the alkyl
chain might affect the solubility of the APIs [16], whereas their toxicity is negligible in relation to the Caco-2
monolayers [16]. To this end, this was a two-tier study, with one aspect focusing on the investigation of
imidazolium-based RTILs for the enhancement of the solubility of AmpB when co-formulated in SNEDDS,
and another focusing on the cytocompatibility of the developed SNEDDS on the Caco-2 cells monolayers.
2. Materials and Methods
2.1. Materials
Amphotericin B was obtained from Alfa Aesar (Kandel, Germany). Propylene glycol, ionic liquids
(namely 1-Butyl-3-methylimidazolium hexafluorophosphate (BMIMPF6) (M.W. 284.18 g/mol), 1-Butyl-3-
methylimidazolium tetrafluoroborate (BMIMBF4) (M.W. 226.02 g/mol) and 1-Hexyl-3-methylimidazolium
chloride (HMIMCl) (M.W. 202.72 g/mol)), Nile Red, bovine serum albumin Triton X-100, coumarin-6,
formaldehyde and N-2-hydroxy-ethylpiperazine-N′-2-ethanesulfonic acid (HEPES) were obtained from
Sigma-Aldrich (Steinheim, Germany). Dulbecco’s modified eagle’s medium (DMEM), penicillin
streptomycin, fetal bovine serum (FBS) and Hanks’ Balanced Salt Solution (HBSS) were purchased
from Gibco™ (Life Technologies, Grand Island, NY, USA). ProLong Gold Antifade Mountant with
4′,6-diamidino-2-phenylindole (DAPI) was purchased from Thermo Fischer Scientific (Walham, MA, USA).
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium / phenazine
methosulfate (MTS/PMS) assay was purchased from Promega (Madison, WI, USA). Polyoxyl 40 hydrogenated
castor oil (Kolliphor RH40) was kindly supplied by BASF (Ludwigshafen, Germany), and Captex® 355
(triglycerides of caprylic/capric acid) was kindly supplied by ABITEC (Columbus, OH, USA). SIF powder
for preparing simulated intestinal fluids was obtained from Biorelevant.com (London, UK). Distilled water
was used in all experimental procedures. All other chemicals and solvents were of analytical grade and
used as received unless otherwise specified.
2.2. Methods
2.2.1. Preparation and Evaluation of SNEDDS Formulations
A previously developed SNEDDS formulation was prepared using Captex® 355 as the oil vehicle
and Kolliphor RH40 as the non-ionic surfactant [25]. Briefly, in a 1:1 blend of oil and surfactant,
10% w/w of Propylene Glycol was added as co-solvent. The mixture was stirred at 37 ◦C until
homogeneity. Subsequently, three different RTILs were incorporated into the SNEDDS preconcentrates
as follows: 0.3 g of IL was mixed with 0.7 g of SNEDDS), and they were stirred until complete
homogenization (SNEDDS:BMIMBF4, SNEDDS:BMIMPF6 and SNEDDS:HMIMCl), forming clear
isotropic preconcentrates.
The SNEDDS preconcentrates (in the presence and absence of RTILs) were evaluated by visual
inspection over a period of 24 h at ambient temperature. The formulations were characterized as stable
when no precipitation or phase separation occurred at the end of this time period. SNEDDS were
dispersed in water, and a dilution factor of 100 (v/v) times was studied. Dispersions of all formulations
were evaluated by Dynamic Light Scattering (DLS). In addition, the self-emulsification time was also
assessed. The emulsification time, the time required by the preconcentrate to form a homogeneous
nanoemulsion [26], was determined by the addition of the proper amount of SNEDDS preconcentrate
to water (1:100 v/v dispersion ratio). The addition of SNEDDS was conducted by pipetting under
gentle agitation. The self-emulsification time is the time required by the preconcentrate to form a
homogeneous nanoemulsion when the disappearance of the SNEDDS preconcentrate is observed
visually [26]. The average droplet diameter and the polydispersity index (PDI) of the dispersions were
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measured by DLS and ζ-potential measurements at 25 ◦C using a Malvern Nanosizer ZS (Malvern
Instruments, Malvern, UK).
2.2.2. Fluorescence Spectroscopy
The miscibility of the API with the preconcentrates was monitored using a lipophilic probe by
means of fluorescence spectroscopy. The hydrophobic fluorescent marker Nile Red (NR) was used as a
model drug, and the ability of oils to accommodate lipophilic compounds was elucidated because of
solvatochromism of NR. SNEDDS preconcentrates were dispersed in water, at a 1:100 ratio, with a final
concentration 26 µM of Nile Red [27]. A fluorescence spectroscopy (RF 5301, Shimadzu, Kyoto, Japan)
was used to quantified the drug content. The fluorescent intensity of the samples was determined at
excitation (EX) wavelengths of 546 nm. The emission (EM) spectra were recorded from 550 to 700 nm,
and the excitation and emission slit widths were set at 1.5.
2.2.3. Solubility Studies and Drug Loaded Formulations
To evaluate the effect of RTILs on the solubility of AmpB, an excess amount of the drug was
added to the SNEDDS and SNEDDS:RTILs preconcentrates. After vortex mixing, the samples were
kept under gentle agitation at ambient temperature for three days for equilibration (protected from
light). The equilibrated samples were centrifuged at 10,000× g for 15 min, followed by filtration
through 0.45-µM PVDF filters, and the supernatants were taken and diluted with MeOH-H2O (50:50).
The amount of AmpB thus obtained was quantified by LC-MS/MS. For the AmpB-loaded SNEDDS,
the results for the maximum amount of solubility were used for every formulation.
Solubility studies in distilled water were performed by mixing 50 µL of each preconcentrate
with 4950 µL of water (100 times dilution) and vortexing to ensure that the formulation was well
mixed. The dilutions were kept under gentle agitation at ambient temperature for 2 h. The samples
were centrifuged at 10,000× g for 10 min, and the supernatants were then evaporated until dryness.
The dry residue was reconstituted with 50 µL of MeOH-H2O (50:50), and the samples were analyzed
by LC-MS/MS.
2.2.4. LC-MS/MS Analysis
Chromatography separation was achieved using an Alliance HT Waters 2790 combined with a
SCIEX API 3200TM mass spectrometer in positive mode (+ ESI). Separation was held with an XTerra
MS C18 (2.1 mm × 50 mm, 3.5 µM) column (Waters, Dublin, Ireland) and mobile phases A: water (0.04%
acetic acid, pH = 3.5) and B: methanol. Gradient elution was started from 60% B and increased to 100%
B in 4 min. The flow rate of the mobile phase and the column oven temperature were set at 0.4 mL/min
and 40 ◦C, respectively. Multiple Reaction Monitoring was performed to achieve MS/MS transitions of
AmpB: m/z 924.3 (parent ion) to 743.3 (daughter ion) as the quantifier ion and m/z 924.3 (parent ion) to
267.2 (daughter ion) as the qualifier ion. The declustering potential and collision energy were applied
at 51 V and 35 V, respectively. The source temperature was fixed at 450 ◦C, and the spray voltage was
set at 4500 V. Analyst Software was used for data acquisition and analysis. The calibration standards
of AmpB were diluted in MeOH–H2O (1:1 v/v), and the calibration curve was linear (R2 = 0.999) at a
concentration range of 2 ng/mL to 2 µg/mL.
2.2.5. Stability of Formulations
A long-term stability study was performed by storing the SNEDDS preconcentrates at room
temperature. At two- and four-week intervals, samples were taken, and the size of the droplet
formed upon dispersion (1:100 ratio) was determined. The chemical stability of AmpB in the SNEDDS
preconcentrates was also evaluated over time. The degradation and/or precipitation of freshly prepared
AmpB-loaded SNEDDS was evaluated upon storage over time. Moreover, the stability of AmpB in
simulated gastric fluid (SGF) at pH 1.2 (2.0 g NaCl, 80 mL 1 M HCl/L) and intestinal fluids was evaluated.
A mixture of sodium taurocholate and egg lecithin (SIF powder) was used for the preparation of fasted
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and fed intestinal simulated fluids (FaSSIF pH 6.5 and FeSSIF pH 5). The SNEDDS were incubated
in SGF or in SIF at a 1:100 (v/v) dilution at 37 ◦C with vigorous stirring. The incubation times were
10, 30 and 120 min. The concentration of AmpB was determined at each time point after complete
solubilization in MeOH:H2O 50:50 v/v to clarify the samples. The amount of drug for each study was
analyzed by LC-MS/MS.
2.2.6. Transport of AmpB across Caco-2 Monolayers
For the in vitro testing of oral formulations, a useful surrogate for human intestinal epithelium is
provided by Caco-2 cells. The cells were cultured in DMEM supplemented with 584 g/mL L-glutamine,
90 U/mL penicillin, 90 g/mL streptomycin, 1% (w/v) nonessential amino acids and 10% (v/v) fetal bovine
serum. Cells were maintained at 37 ◦C in a humidified atmosphere of 5% CO2/95% (v/v) air and 90%
relative humidity. Exponentially growing cells were used for all studies.
Caco-2 cells were plated on 12-well Transwell inserts (Corning; Sigma-Aldrich, Steinheim,
Germany) with a porous polycarbonate membrane of 0.4 µM pore size and 1.13 cm2 growth area.
The density of the cells was 2 × 105 cells/cm2, and passage numbers 14–15 were used. The cells
were grown for three weeks, and the medium was changed every other day. After this period,
the transport study was started. In brief, the monolayers were washed with HBSS buffer at 37 ◦C.
The inserts were then immersed in transport buffer, 1000 µL on the basolateral side and 500 µL of
diluted SNEDDS (1:100 v/v) on the apical side. At 120 min, 100 µL from the basolateral side were
collected. After centrifugation at 10,000× g for 10 min, the clear supernatants of the samples were
evaporated until dryness. Reconstitution of the dry samples was performed with 50 µL of MeOH–H2O
(50:50), and then the samples were analyzed by LC-MS/MS.
2.2.7. Measurement of Transepithelial Electrical Resistance
The effect of the SNEDDS formulations on the Caco-2 cell monolayer integrity was evaluated by
monitoring the transepithelial electrical resistance (TEER) as a function of time, using a Voltohmmeter
EVOM (World Precision Instruments, Inc., Sarasota, FL, USA). Monolayers displaying TEER values
above 500 Ω cm2 were considered appropriate for starting the experiment. 2, 1 and 0.5 h before the
transport study, at the beginning (0 h) and at the end (2 h), the TEER values were recorded. After the
end of the experiment, the formulations were removed and the monolayers were washed with HBSS
buffer. Fresh growth medium was added, and the TEER values were recorded for an additional
1320 min to assess the ability of the cells to recover from treatment.
2.2.8. Viability Studies
The biocompatibility of SNEDDS was assessed by performing the MTS/PMS assay. Caco-2 cells
diluted in culture medium at a density of 6 × 104 cells/cm2 were seeded onto 96-well plates and were
then maintained for 48 h to attach. Prior to treatment, the culture media was removed and replaced by
HBSS buffer for washing. The cells were incubated with the SNEDDS dispersed in HBSS at a ratio of
1:100, at 37 ◦C for 1, 2 and 4 h. Subsequently, the formulations were removed, the cells were washed
with buffer and 100 µL of colorimetric MTS/PMS assay was added to each well for 1–2 h at 37 ◦C
(90 rpm). The assay is based on the reduction of MTS tetrazolium by mitochondria in viable cells to a
colored formazan product that is soluble in tissue culture medium. The well plate was protected from
light. The generated formazan dye was measured by absorbance at 492 nm in a microplate reader
(Multiskan MS photometer type 352; Labsystems, Helsinki, Finland).
Cell viability was expressed as the percentage of absorbance of the sample relative to control,
according to the following Equation:
Viability (%) = 100× A− P
N− P (1)
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where A, P and N are the absorbance obtained for the tested formulations, positive control (cells treated
with 1% Triton X-100) and negative control (cells treated with HBSS only), respectively.
2.2.9. Cellular Uptake Studies
Uptake studies of coumarin-6 were conducted by Confocal Laser Scanning Microscopy (CLSM).
Caco-2 cells from passage numbers 38–41 were seeded on 6-well plates, and a sterilized coverslip
was placed at the bottom of each well. The starting concentration of cells was 4.5 × 104 cells/cm2,
and they were cultured for five days to form a monolayer before the initiation of the uptake experiment.
The cells were then incubated in the presence of either formulations (1:100-diluted SNEDDS with
0.5 µg/mL coumarin-6) or coumarin-6 solution in HBSS as control. After 2 h, the supernatant was
discarded, and the attached cells were washed three times with HBSS and were subsequently treated
with a fixation solution of 4% formaldehyde for 20 min. The cells were washed with HBSS buffer and
permeabilized with 0.3% Triton X-100 for 15 min. Cell nuclei were stained with Prolong Gold Antifade
Reagent with DAPI and left in the dark at 4 ◦C. Images was acquired by Confocal Laser Scanning
Microscopy (Zeiss LSM780 CLSM, Oberkochen, Germany) using the appropriate filters. A 40× oil
immersion lens was used.
2.2.10. Statistical and Data Analysis
All data were presented as mean values of four repetitions and the standard deviation (± S.D.).
The results were compared via the Student’s t-test. A p-value of less than 0.05 was considered as being
statistically significant.
3. Results and Discussion
3.1. Characterization of SNEDDS
The SNEDDS formed a fine nanoemulsion over 38–52 s upon dispersion in water under mild
agitation. All SNEDDS preconcentrates were visually inspected and did not show phase separation
over a period of 24 h.
The droplet size and polydispersity index (PDI) of SNEDDS dispersed in water at 1:100 v/v
dilution are shown in Figure 2. The droplet size of SNEDDS in water was 75 ± 3.4 nm, whereas for
SNEDDS:BMIMBF4, SNEDDS:BMIMPF6 and SNEDDS:HMIMCl they were 79 ± 8 (p > 0.05), 52 ± 11
(p < 0.05) and 55 ± 7 nm (p < 0.05), respectively. It has been reported that the addition of imidazolium
cations to the formulation can change the arrangement of the non-anionic and ionic excipients on the
surface of the oil droplets. Thus, this addition can lead to smaller droplet sizes and greater long-term
stability [23]. The PDI values were less than 0.5 for all formulations. The ζ-potential was −5.3 ± 0.4 mV
for SNEDDS and −2.3 ± 0.9, −14.1 ± 2.3 and −1.8 ± 0.6 mV for SNEDDS:BMIMBF4, SNEDDS:BMIMPF6
and SNEDDS:HMIMCl, respectively.
3.2. Fluorescence Spectroscopy
The fluorescence spectra of SNEDDS (Supporting Figure S1) were recorded, and the solvatochromic
behavior of NR was monitored. In all cases with RTILs, it was clear that the samples exhibited a
lower fluorescence intensity compared to the SNEDDS. The reduced intensity of fluorescence seen for
RTIL-free droplet samples relative to that seen for their RTIL-loaded congeners is consistent with the
reduced capacity of the latter to accommodate NR. The fluorescence emission intensities from NR in
SNEDDS:HMIMCl were lower than those from NR in SNEDDS:BMIMBF4 and SNEDDS:BMIMPF6
respectively, indicating a greater exposure to the aqueous phase. Thus, the fluorescent intensity is
proportionally related to the size of the particles hosting the fluorescent dye [27,28].
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3.3. Solubility Studies
The solubility of AmpB was 0.67 ± 0.07 mg/g in the SNEDDS, whereas the presence of RTILs
increased the solubility of AmpB as follows: 1.04 ± 0.15 mg/g for SNEDDS:BMIMBF4, 1.16 ± 0.14
mg/g for SNEDDS:BMIMPF6 and 1.69 ± 0.2 mg/g for SNEDDS:HMIMCl, as shown in Figure 3.
Significantly higher solubilities were obtained when replacing 33% of SNEDDS with RTILs (1.55-fold for
SNEDDS:BMIMBF4, 1.73-fold for SNEDDS:BMIMPF6 and 2.52-fold for SNEDDS:HMIMCl respectively)
(p < 0.05). This might be attributed to the fact that the PF6 salts are more hydrophobic than the BF4
salts [24] and therefore are expecte to dissolve AmpB better. In addition, the high solubility of AmpB
with HMIMCl might be attributed to the longer alkyl chain (hexyl- versus butyl-for the other two) in
the imidazolium cation. The results are in broad agreement with previous studies using imidazolium
salts (PF6−,BF4−,Cl−) as solvents for poorly water-soluble model drugs [18].
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The solubilities of the tested formulations containing AmpB in water were 1170 ± 69 ng/mL for
the plain SNEDDS formulation, 1470 ± 186 ng/mL for SNEDDS:BMIMBF4, 1610 ± 112 ng/mL for
SNEDDS:BMIMPF6 and 1810 ± 77 ng/mL for SNEDDS:HMIMCl, respectively. As evidenced in Table 1,
the incorporation of AmpB in the SNEDDS increased the droplet size and PDI of all formulations.
The droplet size of AmpB-containing SNEDDS was significantly higher (p < 0.05) compared to its
empty congener (an increase from 75 to 154 nm). When RTILs and AmpB were incorporated into the
SNEDDS preconcentrates, the size of the formed droplets ranged between 118 and 166 nm, which is
significantly higher than for the corresponding drug-free SNEDDS (52 to 79 nm, p < 0.05). The lower
particle size recorded for SNEDDS:BMIMPF6 and SNEDDS:HMIMCl, when compared to the empty
SNEDDS formulations, might be explained in terms of membrane fluidity, as it appears that these
RTILs might increase the fluidity of the oil core of the droplets, allowing NR (Supporting Figure S1) to
penetrate deeper (as evidenced by the fluorescence emission spectra) and allowing for a better packing
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of the carrier. In the case of SNEDDS:BMIMBF4, the larger particle size of the produced droplets might
be attributed to the less hydrophobic nature of BF4 when compared to PF6 [29], which in turn affects
its packing. The presence of the ionic liquids slightly decreased the surface charge of the SNEDDS
formulation (with the exception of BMIMPF6) in absolute values, and this might be correlated with the
ionic character of these liquids, as they can act as cationic surfactants [30]. Upon addition of AmpB,
the ζ-potential of the emulsion droplets increased (Table 1). Although the ζ-potential values of all the
tested dispersions was relatively low, droplet stability might be achieved by steric hindrance due to
the presence of Kolliphor RH40.
Table 1. Droplet diameter (nm), polydispersity index (PDI) and ζ-potential (mV) in water at a 1:100
dilution with AmpB.
Sample
Size (nm) PDI ζ-Potential (mV)
without AmpB with AmpB without AmpB with AmpB without AmpB with AmpB
SNEDDS 75 ± 3.4 154 ± 1 0.16 ± 0.05 0.35 ± 0.05 −5.3 ± 0.4 −10.6 ± 1.1
SNEDDS:BMIMBF4 79 ± 8 118 ± 9 0.22 ± 0.02 0.36 ± 0.04 −2.3 ± 0.9 −5.5 ± 0.2
SNEDDS:BMIMPF6 52 ± 11 166 ± 10 0.23 ± 0.06 0.33 ± 0.06 −14.1 ± 2.3 −8.9 ± 1.3
SNEDDS:HMIMCl 55 ± 7 150 ± 7 0.17 ± 0.02 0.27 ± 0.01 −1.8 ± 0.6 −3.8 ± 0.6
3.4. Stability of Formulations
The size of the droplets formed after dispersion of the SNEDDS at 0, 2 and 4 weeks after production
is depicted in Figure 4a. No significant difference in the droplet size distribution was observed for any
of the SNEDDS formulations. This is in accordance with a previous report, according to which RTILs
can keep the formulation stable over time, as a result of which the droplet size distributions of the
formed emulsions remain constant during storage [23].Pharmaceutics 2020, 12, x 9 of 15 
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The AmpB in all SNEDDS over a period of four weeks showed a gradual reduction, as evidenced by
Figure 4b. The SNEDDS recorded the highest loss of drug (up to 31% loss), while the SNEDDS:HMIMCl
recorded a lower decrease of drug (ca. 17% loss) (p < 0.05). The decrease in the AmpB concentration
was due to drug precipitation, which was visually observed. LC-MS/MS chromatograms indicating
the absence of degradation of AmpB are presented in Supporting Figure S2.
The stability of in the four SNEDDS dispersed in simulated gastric and i testinal fluids
was also investigated. In all SNEDDS, th AmpB exhibi a sufficient stability after dispersion in SGF
(Figure 5a), FaSSIF (Figure 5b) and FeSSIF (Figure 5c). There was a reduction of the initial amount of
AmpB over time, not lower than 80% in all cases (p < 0.05). The solubility of AmpB in SGF, FaSSiF and
FeSSiF media was 77.0 ± 0.53 µg/mL, 18.2 ± 0.33 µg/mL and 30.7 ± 0.4 µg/mL, respectively. In the
case of plain SNEDDS, SNEDDS:BMIMBF4, SNEDDS:BMIMPF6 and SNEDDS:HMIMCl, the final
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concentrations of AmpB were 6.7 µg/mL, 10.2 µg/mL, 11.6 µg/mL and 16.9 µg/mL, showing that the
API was below the non-crystalline state in all of the tested media.
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3.5. Transport Studies across Caco-2 Monolayers
The transports of AmpB from SNEDDS and SNEDDS:RTILs, expressed as the cumulative amounts
permeated at 2 h, are shown in Figure 6a. The cumulative amounts of AmpB transported across the
Caco-2 monolayer over 2 h were 4.39 ± 0.03 ng/cm2, 5.22 ± 0.03 ng/cm2 and 10.91 ± 1.01 ng/cm2 for
SNEDDS:BMIMBF4, SNEDDS:BMIMPF6 and SNEDDS:HMIMCl, respectively, which was higher than
for the SNEDDS (3.13 ± 0.15 ng/cm2). The incorporation of BMIMBF4 and BMIMPF6 into SNEDDS did
not show a significant increase in the amount of AmpB when compared to the control (p > 0.05). On the
contrary, SNEDDS:HMIMCl improved the transport of AmpB when compared to SNEDDS (p < 0.05).
This might be attributed to the longer alkyl chain in the imidazolium cation, which further increased the
solvency of AmpB and could in turn affect the transport rate of the API across the Caco-2 monolayers.
In general, medium chain triglycerides, such as Captex®355, are known to possess permeation-
enhancing properties by opening tight junctions [31–33]. The absorption enhancement has been related
to a redistribution of the cytoskeleton and structural dilatations in the tight junctions [34]. On the
other hand, ionic liquids can also improve drug absorption with their positive effect on permeation
attributed to their ionic character. It has been previously reported that imidazolium-based RTILs can
fluidize the cell membrane in order to create pathways for the diffusion of molecules [35].
The incubation of the Caco-cell monolayers with SNEDDS caused a reduction of TEER values of up
to 60% at 2 h (Figure 6b) when compared to no decrease (99%) for the control (p < 0.05). This reduction
might be attributed to the ester derivatives of C8 and C10 fatty acids of Captex® 355, due to their
ability to open the tight junction [36,37]. Upon removal of SNEDDS and substitution of the apical
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medium with fresh growth medium, the monolayers started to slowly recover, and a constant increase
in resistance was recorded. More specifically, at 24 h the TEER reached 70% of the initial TEER
for SNEDDS and SNEDDS:HMIMCl, 66% for SNEDDS:BMIMPF6 and 61% for SNEDDS:BMIMBF4,
when compared to 79% for the control (p < 0.05).
Pharmaceutics 2020, 12, x 10 of 15 
 
3.5. Transport Studies across Caco-2 Monolayers 
The transports of AmpB from SNEDDS and SNEDDS:RTILs, expressed as the cumulative 
amounts permeated at 2 h, are shown in Figure 6a. The cumulative amounts of AmpB transported 
across the Caco-2 monolayer over 2 h were 4.39 ± 0.03 ng/cm2, 5.22 ± 0.03 ng/cm2 and 10.91 ± 1.01 
ng/cm2 for SNEDDS:BMIMBF4, SNEDDS:BMIMPF6 and SNEDDS:HMIMCl, respectively, which was 
higher than for the SNEDDS (3.13 ± 0.15 ng/cm2). The incorporation of BMIMBF4 and BMIMPF6 into 
SNEDDS did not show a significant increase in the amount of AmpB when compared to the control 
(p > 0.05). On the contrary, SNEDDS:HMIMCl improved the transport of AmpB when compared to 
SNEDDS (p < 0.05). This might be attributed to the longer alkyl chain in the imidazolium cation, which 
further increased the solvency of AmpB and could in turn affect the transport rate of the API across 
the Caco-2 monolayers. 
In general, medium chain triglycerides, such as Captex®355, are known to possess permeation-
enhancing properties by opening tight junctions [31–33]. The absorption enhancement has been 
related to a redistribution of the cytoskeleton and structural dilatations in the tight junctions [34]. On 
the other hand, ionic liquids can also improve drug absorption with their positive effect on 
permeation attributed to their ionic character. It has been previously reported that imidazolium-
based RTILs can fluidize the cell membrane in order to create pathways for the diffusion of molecules 
[35]. 
The incubation of the Caco-cell monolayers with SNEDDS caused a reduction of TEER values of 
up to 60% at 2 h (Figure 6b) when compared to no decrease (99%) for the control (p < 0.05). This 
reduction might be attributed to the ester derivatives of C8 and C10 fatty acids of Captex® 355, due 
to their ability to open the tight junction [36,37]. Upon removal of SNEDDS and substitution of the 
apical medium with fresh growth medium, the monolayers started to slowly recover, and a constant 
increase in resistance was recorded. More specifically, at 24 h the TEER reached 70% of the initial 
TEER for SNEDDS and SNEDDS:HMIMCl, 66% for SNEDDS:BMIMPF6 and 61% for 
SNEDDS:BMIMBF4, when compared to 79% for the control (p < 0.05). 
Moreover, the solubility studies revealed that the presence of RTILs significantly increased the 
solubility of AmpB when compared to the plain SNEDDS formulation. These data show that the 
increased transport of AmpB across Caco-2 monolayers in the presence of RTILs might be attributed 
to the ability of RTILs to both increase the solubility of AmpB and, at the same time, cause a reduction 
of the TEER values. 
(a) (b) 
Figure 6. (a) Total accumulated amount of AmpB across the Caco-2 monolayer and (b) TEER values. 
3.6. Cell Viability 
The cytocompatibility of the different SNEDDS was assessed on the Caco-2 cell line in a time-
dependent manner using the MTS/PMS assay (Figure 7). No obvious cytotoxicity (> 80%) was 
observed for the cell treatment with SNEDDS at the different time points that were measured (1, 2 
Figure 6. (a) Total accu ulated a ount of pB across the Caco-2 monolayer and (b) TEER values.
Moreover, the solubility studies revealed that the presence of RTILs significantly increased the solubility
of AmpB when compared to the plain SNEDDS formulation. These data show that the increased transport
of AmpB across Caco-2 monolayers in the presence of RTILs might be attributed to the ability of RTILs to
both increase the solubility of AmpB and, at the same time, cause a reduction of the TEER values.
3.6. Cell Viability
The cytocompatibility of the different SNEDDS was assessed on the Caco-2 cell line in a time-dependent
manner using the MTS/PMS assay (Figure 7). No obvious cytotoxicity (>80%) was observed for the cell
treatment with SNEDDS at the different time points that were measured (1, 2 and 4 h). Cell viability was
retained at over 61% for all SNEDDS with RTILs, showing a decrease as a function of time (p < 0.05).
Approximately 61%, 63% and 72% of the Caco-2 cells were viable after 4 h of the experiment for BMIMBF4,
BMIMPF6 and HMIMCl, respectively. These values indicate that SNEDDS with RTILs exhibited a slightly
toxic effect on the cells. The results obtained in the current study are in broad agreement with previous
studies, where a low or moderate toxicity of RTILs has been observed in different cell lines [17,23,38].
3.7. Cellular Uptake
The cellular uptake and intracellular distribution of coumarin-6 in Caco-2 cells was investigated by
CLSM after cell exposure to SNEDDS and SNEDDS:RTILs. The white arrow in Figure 8a shows that, upon
incubation with Caco-2 monolayers, the coumarin-6 solution (control) is located close to the cytoplasm [39,40].
Images of SNEDDS containing coumarin-6, shown as green spots closely located to the nuclei and illustrated
with a white arrow, are shown in Figure 8b. For SNEDDS containing BMIMBF4, the images show a more
intense fluorescence of coumarin-6 in the intercellular spaces co-existing with green particles (Figure 8c)
when compared to their plain congener, and this more intense fluorescence is shown by a white arrow.
When BMIMPF6 is co-formulated with SNEDDS, the coumarin-6 fluorescence is also present in the
intercellular space (Figure 8d). The fluorescence staining for BMIMPF6 formulations appears to be more
intense when compared to BMIMBF4. Finally, when SNEDDS containing HMIMCl were incubated with
Caco-2 monolayers, increased numbers of green particles and increased fluorescence staining were observed
(Figure 8e). The area with increased green particles and fluorescence staining is shown by a white arrow.
In parallel, this exposure of Caco-2 cells to SNEDDS and SNEDDS:RTILS does not appear to affect nuclei,
since no substantial cell nuclei swelling and fragmentation was observed in the treated cultures when
compared to the control.
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4. Conclusions
Incorporating RTILs into SNEDDS formulations slightly increased the droplet size and the
PDI, while decreasing the ζ-potential. The rank order of solubility of AmpB in SNEDDS was as
follows: SNEDDS:HMIMCl > SNEDDS:BMIMPF6 > SNEDDS:BMIMBF4 > SNEDDS. The ability
of RTILs to increase solubility depends on their anions (PF6−, BF4−, Cl−) and the length of their
alkyl chain. Although promising, the solubility values obtained in the current study for AmpB
in the presence of RTILs are relatively low from a clinical perspective. From this point of view,
the possibility of co-formulating a second RTIL might be considered as a strategy to increase the
drug’s solubility [16]. RTILs also enhanced the transport of AmpB across Caco-2 monolayers, with the
same order as for the solubility results. In addition, the presence of RTILs resulted in more stably
dispersed formulations when compared with their empty congeners, as evidenced by their droplet size
distributions after four weeks. However, SNEDDS with RTILs exhibited a slightly toxic effect on the
cells as a function of time. In conclusion, the array of new RTIL-lipid-based drug delivery strategies
provide interesting perspectives, including a high drug-loading capacity and the ability to increase
drug permeation profiles.
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Figure S1: Fluorescence spectra of the SNEDDS diluted at 1:100 in water. Figure S2: Chromatograms of LC-MS/MS
of (a) SNEDDS, (b) SNEDDS:BMIMBF4, (c) SNEDDS:BMIMPF6 and (d) SNEDDS:HMIMCl after four weeks.
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